Sarepta

Pharma News
Juvenescence nets USD 100M; Sarepta DMD drug faces rejection

Juvenescence closes a USD 100 Million Series B round Juvenescence, a life sciences company focused on treating ageing problems, has successfully raised USD 100 Million in a Series B round. The...


The Business Cocktail

Cell Medica receives funds for its cell therapy A USD 8.7 million grant to Cell Medica has been given by Cancer Prevention and Research Institute of Texas (CPRIT) to speed up the clinical deve...


Default Blog Image
Sarepta’s deal; Fund raisings for Apexigen; Novo funded rare disease startup

Sarepta builds in gene therapy with $30M Lacerta deal Sarepta has dampen its enthusiasm for an ongoing gene therapy candidate. Sarepta has made a tie-up with lacerta that will add 3 more programs ...


Sarepta’s Unusual Journey

Before approving an investigational drug, safety and effectivity needs to be proven. Something different happened with Sarepta’s Muscular dystrophy drug Eteplirsen, as its luck changed completely w...


Editor's Pick
Can denovoSkin Be A Lifesaver for Burn Victims?

Burn is a global public health problem, causing more than 180,000 deaths per year acros...

NexoBrid and its Awaiting US Approval

A Burn takes place when the skin comes into contact with a heat source. Burns can occur...

New Clinical Developments in the Pulmonary Arterial Hypertension Treatment Do...

Pulmonary arterial hypertension is a progressive disease of the lung vascular system, p...

Commercial Roadmap for the Launch: What can Biopharmaceuticals do to Increase...

The Pharma and Biotech Healthcare market has been an ever-changing industry in terms of...

Emerging Market for Organ on a Chip

The organ on a chip is a microfluidic culture device that recapitulates the complicated...

ASCO Conference 2022
ASCO Conference 2022

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.